(Q38186704)

30 August 2017

title

Genetic alterations and personalized medicine in melanoma: progress and future prospects (English)

1 reference

30 August 2017

main subject

personalized medicine

1 reference

2

1 reference

30 August 2017

6

1 reference

30 August 2017

4

Keith T Flaherty

1 reference

30 August 2017

5

Dirk Schadendorf

1 reference

30 August 2017

Klaus G Griewank

1

1 reference

30 August 2017

John F Thompson

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

Journal of the National Cancer Institute

30 August 2017

published in

1 reference

30 August 2017

volume

106

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

djt435

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

HIV-1 antiretroviral drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Germline p16 mutations in familial melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

21 January 2018

When is fever malaria?

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Prognostic implications of monosomy 3 in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Integrative genomic analysis of aneuploidy in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

The RAF proteins take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

B-raf, a new member of the raf family, is activated by DNA rearrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Activation of N-ras in a human melanoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Clinical correlates of NRAS and BRAF mutations in primary human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Large-scale analysis of KIT aberrations in Chinese patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

G-protein-coupled receptors and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Functions and regulatory mechanisms of Gq-signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Mutations in GNA11 in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Mechanism of GTP hydrolysis by G-protein alpha subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A cell cycle regulator potentially involved in genesis of many tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

The retinoblastoma protein and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Genetics: what advice for patients who present with a family history of melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

How to make a melanoma: what do we know of the primary clonal events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Elucidating distinct roles for NF1 in melanomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Frequent mutation of BAP1 in metastasizing uveal melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

BAP1 loss defines a new class of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Germline mutations in BAP1 predispose to melanocytic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Germline BAP1 mutations predispose to malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Molecular classification of cutaneous malignant melanoma by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Predicting clinical outcome through molecular profiling in stage III melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Review and cross-validation of gene expression signatures and melanoma prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Melanoma molecular classes and prognosis in the postgenomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Molecular profiling of melanoma and the evolution of patient-specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A landscape of driver mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Exome sequencing identifies GRIN2A as frequently mutated in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

TERT promoter mutations in familial and sporadic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Highly recurrent TERT promoter mutations in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

SWI/SNF nucleosome remodellers and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

SWItching on the transcriptional circuitry in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Loss of BMI-1 expression is associated with clinical progress of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

GNAQ and GNA11 mutations in melanocytomas of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Novel somatic mutations to PI3K pathway genes in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Improving melanoma classification by integrating genetic and morphologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Genetic and morphologic features for melanoma classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Sunitinib therapy for melanoma patients with KIT mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A mutation hotspot at the p14ARF splice site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Malignant melanoma: genetics and therapeutics in the genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

MC1R variants, melanoma and red hair color phenotype: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Enhanced detection of spitzoid melanomas using fluorescence in situ hybridization with 9p21 as an adjunctive probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A proposal for improving multicolor FISH sensitivity in the diagnosis of malignant melanoma using new combined criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Major response to everolimus in melanoma with acquired imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A phase 2 trial of dasatinib in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Inferring tumor progression from genomic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Tumour evolution inferred by single-cell sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Tumor self-seeding by circulating cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Epigenetic biomarkers in skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT435

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJT435

1 reference

30 August 2017

1 reference